Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Avalo Therapeutics stock price, quote, forecast and news

AVTX
US05338F2074

Price

9.42
Today +/-
+0.70
Today %
+8.62 %
P

Avalo Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Avalo Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Avalo Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Avalo Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Avalo Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Avalo Therapeutics Stock Price History

DateAvalo Therapeutics Price
9/17/20249.42 undefined
9/16/20248.64 undefined
9/13/20248.98 undefined
9/12/20248.99 undefined
9/11/20248.20 undefined
9/10/20248.10 undefined
9/9/20248.15 undefined
9/6/20247.56 undefined
9/5/20247.70 undefined
9/4/20247.52 undefined
9/3/20247.91 undefined
8/30/20247.00 undefined
8/29/20249.05 undefined
8/28/20249.50 undefined
8/27/202410.96 undefined
8/26/202410.00 undefined
8/23/20249.20 undefined
8/22/20248.45 undefined
8/21/20248.65 undefined
8/20/20248.91 undefined

Avalo Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Avalo Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Avalo Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Avalo Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Avalo Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Avalo Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Avalo Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Avalo Therapeutics’s growth potential.

Avalo Therapeutics Revenue, EBIT and net profit per share

DateAvalo Therapeutics RevenueAvalo Therapeutics EBITAvalo Therapeutics Net Income
2028e0 undefined-48.96 M undefined0 undefined
2027e0 undefined-44.88 M undefined0 undefined
2026e0 undefined-39.78 M undefined-1.6 M undefined
2025e0 undefined-36.72 M undefined-6.89 M undefined
2024e0 undefined-59.26 M undefined-8.17 M undefined
20231.92 M undefined-23.44 M undefined-31.54 M undefined
202218.05 M undefined-37.44 M undefined-41.66 M undefined
20215.4 M undefined-82.13 M undefined-84.38 M undefined
20206.7 M undefined-47.29 M undefined-63.5 M undefined
20196.75 M undefined-16.14 M undefined-16.07 M undefined
20187.03 M undefined-14.79 M undefined-41.71 M undefined
201727.81 M undefined13.89 M undefined11.87 M undefined
20161.15 M undefined-16.08 M undefined-16.47 M undefined
20150 undefined-11.01 M undefined-10.49 M undefined
20140 undefined-17.12 M undefined-3.52 M undefined
20130 undefined-12.93 M undefined-13.13 M undefined
201280,000 undefined-10.49 M undefined-10.49 M undefined
2011210,000 undefined-3.45 M undefined-3.48 M undefined

Avalo Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
00000127766518100000
------2,600.00-74.07-14.29--16.67260.00-94.44-----
------100.0042.86116.67100.0060.0077.78------
00000027376314000000
-3-10-12-17-11-1613-14-16-47-82-37-23-59-36-39-44-48
------1,600.0048.15-200.00-266.67-783.33-1,640.00-205.56-2,300.00-----
-3-10-13-3-10-1611-41-16-63-84-41-31-8-6-100
-233.3330.00-76.92233.3360.00-168.75-472.73-60.98293.7533.33-51.19-24.39-74.19-25.00-83.33--
0.720.720.720.720.720.741.562.93.575.568.329.410.2800000
------------------
Details

Keystats

ⓘ

Revenue and Growth

The Avalo Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Avalo Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (k)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
1.119.523.4211.7421.165.132.4710.6511.2418.9254.5913.177.42
0000002.940.8212.181.0600
0000004.175.264.242.213.741.920
00000038032020040200
0.110.430.710.420.460.40.74.881.232.72.421.310.84
1.229.954.1312.1621.625.5310.6621.9317.7326.0161.8516.428.26
0.060.060.070.040.040.040.040.591.451.612.72.411.97
0000000000000
0000000000000
00000017.663.772.431.590.0400
00000014.2914.4114.4114.4114.4114.4110.5
00.010.870.1200.060.1329.560.10.151.230.130.13
0.060.070.940.160.040.132.1248.3318.3917.7618.3816.9512.6
1.2810.025.0712.3221.665.6342.7870.2636.1243.7780.2333.3720.86
                         
0.0219.8819.8828.350.010.010.030.040.040.080.110.010
0.982.579.1516.7466.6470.2383.34119.08135.24202.28285.14292.9342.44
-3.48-13.97-27.02-43.07-53.56-70.04-58.17-98.22-114.29-177.79-262.17-303.82-335.13
0000002.66000000
0000000000000
-2.488.482.012.0213.090.227.8620.920.9924.5723.08-10.917.3
0.240.821.640.930.681.011.31.452.082.573.372.880.45
0.310.720.990.981.890.946.795.375.5711.3116.1412.714.17
0.1800.431.180.080.01319.44.521.340.380.60
3.04000000000000
0001.913.212.35000005.930
3.771.543.0655.864.3111.0926.2212.1715.2219.8922.124.62
0005.312.350000032.8313.490
00000010709090110140155
00000.371.253.8523.062.873.884.38.548.92
0005.312.721.253.8623.132.963.9737.2422.179.07
3.771.543.0610.318.585.5614.9549.3515.1319.1957.1344.2913.69
1.2910.025.0712.3321.675.7642.8170.2536.1243.7680.2133.3820.99
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Avalo Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Avalo Therapeutics's financial health and stability.

Assets

Avalo Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Avalo Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Avalo Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Avalo Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-3-10-13-16-10-1611-40-16-63-84-41-31
0000000431100
0000000000000
00000008-2-424-9
100001123-425899
0000000010121
000000001,0000000
-1-9-11-15-10-1412-3-19-40-70-26-30
0000000000000
000000-180011000
000000-181011000
0000000000000
3009-1-3-200032-14-21
01761423216104073046
31752319-13101244106-1425
0000-204323000
0000000000000
18-689-16-28-71535-41-5
-1.91-9.3-11.52-15.54-10.18-14.612.56-3.69-19.39-40.6-71-26.85-30.84
0000000000000

Avalo Therapeutics stock margins

The Avalo Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Avalo Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Avalo Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Avalo Therapeutics's sales revenue. A higher gross margin percentage indicates that the Avalo Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Avalo Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Avalo Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Avalo Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Avalo Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Avalo Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Avalo Therapeutics Margin History

Avalo Therapeutics Gross marginAvalo Therapeutics Profit marginAvalo Therapeutics EBIT marginAvalo Therapeutics Profit margin
2028e33.26 %0 %0 %
2027e33.26 %0 %0 %
2026e33.26 %0 %0 %
2025e33.26 %0 %0 %
2024e33.26 %0 %0 %
202333.26 %-1,218.5 %-1,639.5 %
202281 %-207.42 %-230.8 %
202172.41 %-1,520.93 %-1,562.59 %
202095.52 %-705.82 %-947.76 %
2019108.44 %-239.11 %-238.07 %
201853.63 %-210.38 %-593.31 %
201797.73 %49.95 %42.68 %
201633.26 %-1,398.26 %-1,432.17 %
201533.26 %0 %0 %
201433.26 %0 %0 %
201333.26 %0 %0 %
201233.26 %-13,112.5 %-13,112.5 %
201133.26 %-1,642.86 %-1,657.14 %

Avalo Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Avalo Therapeutics earnings per share therefore indicates how much revenue Avalo Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Avalo Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avalo Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avalo Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avalo Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Avalo Therapeutics Revenue, EBIT and net profit per share

DateAvalo Therapeutics Sales per ShareAvalo Therapeutics EBIT per shareAvalo Therapeutics Earnings per Share
2028e0 undefined0 undefined0 undefined
2027e0 undefined0 undefined0 undefined
2026e0 undefined0 undefined-1.55 undefined
2025e0 undefined0 undefined-6.69 undefined
2024e0 undefined0 undefined-7.94 undefined
20236.93 undefined-84.41 undefined-113.58 undefined
20221.92 undefined-3.98 undefined-4.43 undefined
20210.65 undefined-9.87 undefined-10.14 undefined
20201.21 undefined-8.51 undefined-11.42 undefined
20191.89 undefined-4.52 undefined-4.5 undefined
20182.42 undefined-5.1 undefined-14.38 undefined
201717.83 undefined8.9 undefined7.61 undefined
20161.55 undefined-21.73 undefined-22.26 undefined
20150 undefined-15.29 undefined-14.57 undefined
20140 undefined-23.78 undefined-4.89 undefined
20130 undefined-17.96 undefined-18.24 undefined
20120.11 undefined-14.57 undefined-14.57 undefined
20110.29 undefined-4.79 undefined-4.83 undefined

Avalo Therapeutics business model

Avalo Therapeutics is one of the most popular companies on Eulerpool.com.

Avalo Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Avalo Therapeutics Revenue by Segment

Segmente202320222021202020192018
License and other revenue-14.69 M USD----
Product revenue, net-3.4 M USD----
Product revenue, net1.4 M USD-4.8 M USD6.7 M USD--
License revenue--600,000 USD---
License and other revenue500,000 USD-----
AVTX-611-200,000 USD----
License and other revenue------
Product revenue, net-----17.87 M USD
Sales force revenue-----456,056 USD
License and other revenue----100,000 USD-
Grant revenue------
Product revenue, net----6.65 M USD-
Sales force revenue------
Prescription drugs-----10.19 M USD
Prescribed dietary supplements-----7.68 M USD
Prescription drugs----6.65 M USD-

Avalo Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Avalo Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Avalo Therapeutics shares outstanding

The number of shares was Avalo Therapeutics in 2023 — This indicates how many shares 277,730 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Avalo Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Avalo Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Avalo Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Avalo Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Avalo Therapeutics Stock splits

In Avalo Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Avalo Therapeutics.

Avalo Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-6.83 -14.07  (-105.88 %)2024 Q2
3/31/2024-1.2 -141  (-11,614.86 %)2024 Q1
12/31/2023-4.9 -116.22  (-2,273.67 %)2023 Q4
9/30/2023-269.28 -26.4  (90.2 %)2023 Q3
6/30/2023-195.84 -141.6  (27.7 %)2023 Q2
3/31/2023-237.46 -204  (14.09 %)2023 Q1
12/31/2022-179.52 -249.6  (-39.04 %)2022 Q4
9/30/2022-1.12 0.34  (130.44 %)2022 Q3
6/30/2022-1.81 -1.38  (23.56 %)2022 Q2
3/31/2022-1.63 -2.4  (-47.06 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the Avalo Therapeutics stock

Eulerpool World ESG Rating (EESG©)

44/ 100

🌱 Environment

48

👫 Social

50

🏛️ Governance

36

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Avalo Therapeutics list of shareholders

%
Name
Stocks
Change
Date
4.08738 % Nantahala Capital Management, LLC42,10042,10012/31/2023
1.54078 % BlackRock Institutional Trust Company, N.A.15,87015,44012/31/2023
0.44699 % Ostrum Asset Management4,6044,60412/31/2023
0.17146 % Tower Research Capital LLC1,7661,55912/31/2023
0.07379 % Golestaneh (Cambyz)76004/18/2023
0.05068 % FNY Investment Advisers LLC52252212/31/2023
0.03282 % Banque Cantonale Vaudoise3383383/31/2024
0.01388 % Boyd (Steven J)14306/27/2023
0.01340 % RBC Capital Partners13813612/31/2023
0.00583 % Neil Garry Arthur6053/15/2024
1
2
3
4
5
...
9

Avalo Therapeutics Executives and Management Board

Dr. Garry Neil70
Avalo Therapeutics Chairman of the Board, President, Chief Executive Officer (since 2020)
Compensation 1.33 M
Mr. Christopher Sullivan39
Avalo Therapeutics Chief Financial Officer
Compensation 768,549
Dr. Magnus Persson63
Avalo Therapeutics Lead Independent Director
Compensation 85,559
Mr. Mitchell Chan42
Avalo Therapeutics Independent Director
Compensation 72,559
Dr. Gilla Kaplan76
Avalo Therapeutics Independent Director
Compensation 72,559
1
2

Most common questions regarding Avalo Therapeutics

What is the P/E ratio of Avalo Therapeutics 2024?

The Avalo Therapeutics P/E ratio is -0.32.

What is the P/S ratio of Avalo Therapeutics 2024?

The Avalo Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Avalo Therapeutics?

The AlleAktien quality score for Avalo Therapeutics is 2/10.

What is the revenue of Avalo Therapeutics 2024?

The revenue cannot currently be calculated for Avalo Therapeutics.

How high is the profit of Avalo Therapeutics 2024?

The expected Avalo Therapeutics profit is -8.17 M USD.

What is the business model of Avalo Therapeutics

No history available for Avalo Therapeutics.

What is the Avalo Therapeutics dividend?

Avalo Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Avalo Therapeutics pay dividends?

The dividend cannot currently be calculated for Avalo Therapeutics or the company does not pay out a dividend.

What is the Avalo Therapeutics ISIN?

The ISIN of Avalo Therapeutics is US05338F2074.

What is the Avalo Therapeutics ticker?

The ticker of Avalo Therapeutics is AVTX.

How much dividend does Avalo Therapeutics pay?

Over the past 12 months, Avalo Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Avalo Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Avalo Therapeutics?

The current dividend yield of Avalo Therapeutics is .

When does Avalo Therapeutics pay dividends?

Avalo Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Avalo Therapeutics?

Avalo Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Avalo Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Avalo Therapeutics located?

Avalo Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Avalo Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Avalo Therapeutics from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did Avalo Therapeutics pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of Avalo Therapeutics in the year 2023?

In the year 2023, Avalo Therapeutics distributed 0 USD as dividends.

In which currency does Avalo Therapeutics pay out the dividend?

The dividends of Avalo Therapeutics are distributed in USD.

All fundamentals about Avalo Therapeutics

Our stock analysis for Avalo Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Avalo Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.